Co-Invest: Inside GRIDX Capital’s Collaborative Venture Model Leading a Life-Centered Revolution in Planet-First Companies

Written By maya lockwood

GRIDX CAPITAL, a global venture fund at the forefront of the Life-Centered Revolution, is shaping a more sustainable future by drawing inspiration from nature’s blueprint. Headquartered in Buenos Aires, Argentina, GRIDX CAPITAL has global ambitions and a proven track record. It’s not just investing in breakthrough science—it’s building a next-generation venture ecosystem where deep research becomes scalable, globally relevant businesses.

GRIDX CAPITAL has engaged with stakeholders across major U.S. innovation hubs, providing them with early access and informational insights to underexplored frontiers of innovation through a trusted and experienced partner.

The Strategic Opportunity: Entering the Life-Based Economy

Venture capital is shifting from software-centric bets to planet-centric solutions that integrate biology, AI, and materials science. Synthetic biology alone is projected to exceed $30 billion annually within the next few years.

Leading this transition isn’t just smart—it’s necessary. Venture funds that act now will be positioned to benefit from what McKinsey calls the emerging bioeconomy, spanning sectors from health to energy to agriculture.

This is where GRIDX CAPITAL excels—identifying scientific breakthroughs, building companies around them from the earliest stages, and co-investing with global partners to scale. 

Think of GRIDX CAPITAL as having access to the best research labs—located in the most biodiverse region on Earth: Latin America.

Why GRIDX CAPITAL Is the Ideal Co-Investment Partner

De-Risking Deep Science at the Source
GRIDX CAPITAL screens thousands of early-stage research projects—over 5,500 to date—to identify those with the highest commercial potential. These discoveries are rigorously validated and transformed into venture-ready startups through a hands-on, 6–12 month company building process.

By the time U.S. co-investors come in, the science is validated, the team is in place, and the company meets global investor standards. This early de-risking shortens the path from lab to market and builds investor confidence.

Company Building at Scale
With 92 startups launched and a network of more than 1,000 engaged scientists, GRIDX CAPITAL operates one of the most advanced life sciences venture platforms in the Global South. Their integrated model includes:

  • Cross-functional team formation: Besides the scientific teams, GRIDX CAPITAL rigorously selects and brings in talented business profiles to complement the scientists' skills in the co-founding teams. 

  • Capital deployment: GRIDX CAPITAL invests USD 250K after the first stage of its process and up to USD 1M in follow-on investments during seed and Series A rounds.

  • Companies incorporated in U.S.: The portfolio companies are incorporated in Delaware. But their scientific teams initially remain in Latin America, where R&D costs are significantly lower, and relocate to the US as they grow.

This holistic approach is designed to meet the expectations of international follow-on capital. 

Regional Expertise, Global Standards
But what truly sets the GRIDX CAPITAL model apart is its originality and deep experience in Latin America: they are pioneers in what they do and have been doing it for over 8 years. They understand the particularities and mindset of Latin American scientists and continuously iterate on their process to provide the right stimuli for them to make the leap into the startup world. Though based in Latin America, GRIDX CAPITAL operates with global best practices in compliance, financial discipline, and investor transparency—seamlessly blending local insight with international execution.

A Proven Track Record with Global Stakeholders

GRIDX CAPITAL has already co-invested with over 50 international venture funds, including 23 in the U.S., across major biotech and agtech hubs, including SOSV, At One Ventures, Corteva Catalyst, Draper Associates, Ospraie, The Gates Foundation, among others. 

Portfolio Highlights: 

Stamm

Pioneering the use of microfluidics for industrial-scale precision fermentation. It was one of the first Latin American companies to join the IndieBio (SOSV) portfolio—paving the way for others in the region—and is backed by Draper Associates and Varana Capital. Stamm operates world-class facilities in Buenos Aires and Switzerland.

Puna Bio

First company in the world to harness extremophile bacteria to develop biofertilizers. They recently closed a Series A round led by Corteva and already have two products on the market, with operations in the US, Brazil, Paraguay, and Argentina.

GRIDX CAPITAL-backed startups have secured over $100 million in follow-on capital—much of it from U.S. investors.

Scaled for the Planet

Latin America is rapidly emerging as a global hub for bio-innovation, driven by its unparalleled biodiversity, cost-effective scientific talent, and abundant underutilized intellectual property. Home to the richest biological reservoirs on Earth, the region provides critical raw materials and expertise essential to advancing life sciences and biotechnology.

With over 200,000 trained life scientists working at a fraction of U.S. R&D costs, Latin America offers a deep, affordable talent pool. Its real-world validation environments enable faster, more cost-effective testing and iteration—accelerating development cycles and enhancing readiness for global markets.

GRIDX CAPITAL is uniquely equipped to transform these advantages into globally investable companies. By combining local insight with rigorous, hands-on company building, GRIDX CAPITAL bridges frontier innovation and global capital, creating scalable ventures designed to make planetary impact.

How Do GRIDX CAPITAL Companies Use AI 

Biotech is digital today, and that’s why thinking about biotech inevitably means thinking about artificial intelligence. AI is increasingly essential for analyzing biological data, designing and optimizing metabolic pathways and molecules, predicting behavior under different conditions, and automating complex processes. In this context, some companies in the GRIDX CAPITAL portfolio—particularly those focused on bioinformatics—have naturally engaged with data science and machine learning.

However, many other companies in the portfolio do not have team members with expertise in bioinformatics. They generate valuable experimental data but often lack the tools, infrastructure, or in-house capabilities to analyze it effectively. To address this, GRIDX CAPITAL launched a dedicated startup that provides AI and data science services both to portfolio companies and to the broader biotech ecosystem. This allows early-stage teams to access advanced modeling, simulation, and analysis without the need to build internal capabilities from scratch. GRIDX CAPITAL’s vision is clear: in the near future, no biotech company will exist without an AI strategy.

Strategic Synergy of the U.S. Ecosystem 

For U.S. venture funds, partnering with GRIDX CAPITAL provides a complementary model: U.S. investors bring growth capital, commercialization expertise, and access to global exit pathways. GRIDX CAPITAL contributes access to breakthrough IP, exceptional scientific talent, early-stage company formation, and exposure to biodiversity-rich emerging markets. As an example, last year GRIDX CAPITAL partnered with Atento Capital in Tulsa to launch a 3.5-week program helping Latin American startups refine their go-to-market strategies and explore Tulsa as a potential U.S. base. Over two editions, more than 20 portfolio startups have already taken part. This kind of partnership unlocks a compelling thesis that merges Latin America’s untapped potential with the U.S. ecosystem’s ability to scale and commercialize innovation on a global stage.

Meet the GRIDX CAPITAL Team, The Magic and The Genius

At the core of GRIDX CAPITAL is a dedicated leadership team committed to transforming scientific discoveries into impactful life science startups. Co-founders Miguel Galuccio (Chairman) and Matías Peire (CEO) provide visionary direction and strategic expertise, while Maria Renner (Partner & CSO) and Federico Marque (Partner & COO) lead scientific and operational execution with excellence.

Supporting them is a multidisciplinary team of experts spanning science, business, legal, communications, and international operations, including:

Collaborative Opportunities with Co-Investment Partners | General Information (Not an Offer to Invest)

Stakeholders worldwide are increasingly focused on the convergence of biology and technology to tackle the planet’s most urgent challenges—from food systems and materials to healthcare. The future belongs to regenerative, science-driven innovation.

GRIDX CAPITAL offers more than just deal flow; it presents a mission-driven, scalable thesis rooted in life sciences, sustainability, and global inclusion. With deep roots in Latin America and a growing global footprint, GRIDX CAPITAL is designed for partners ready to lead—not follow—the next frontier of bio-based innovation.

For accredited investors and institutional partners, GRIDX CAPITAL’s model demonstrates how breakthrough science can be scaled for impact.

Learn more about our collaborative venture model

www.gridexponential.com  | GRIDX CAPITAL | LinkedIn 

For informational purposes only; not an offer to sell or a solicitation to buy any security. Please contact GRIDX CAPITAL for more information.

Disclaimer: This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction. Any such offer or solicitation will be made only by means of formal offering documents and in compliance with applicable securities laws. Any potential investment opportunity is intended solely for qualified institutional buyers or accredited investors, as defined under applicable U.S. securities laws. Past performance is not indicative of future results

maya lockwood
Next

David Jepson: The Evolving Role of CEO